Long-Term Treatment With Cisapride and Antibiotics in Liver Cirrhosis: Effect on Small Intestinal Motility, Bacterial Overgrowth, and Liver Function
Abstract
OBJECTIVES: Altered small-bowel motility, lengthening of the orocecal transit time, and small-intestinal bacterial overgrowth have been described in patients with liver cirrhosis. These changes might be related to the progressive course and poor prognosis of the disease. We investigated the effect of a long-term treatment with cisapride and an antibiotic regimen on small-intestinal motor activity, orocecal transit time, bacterial overgrowth, and some parameters of liver function. METHODS: Thirty-four patients with liver cirrhosis of different etiology entered in the study. They were randomly allocated to receive cisapride (12), an alternating regimen of norfloxacin and neomycin (12), or placebo (10) during a period of 6 months. At entry and at 3 and 6 months, a stationary small-intestinal manometry was performed, and orocecal transit time and small-intestinal bacterial overgrowth were also investigated using the H2 breath test. Liver function was estimated with clinical and laboratory measurements (Child-Pugh score). RESULTS: After 6 months, both cisapride and antibiotics significantly improved fasting cyclic activity, reduced the duration of orocecal transit time, and decreased small-intestinal bacterial overgrowth. Cisapride administration was followed also by an increase in the amplitude of contractions. No statistically significant variations in these parameters were observed with placebo. An improvement of liver function was observed at 3 and 6 months with both cisapride and antibiotics. CONCLUSIONS: Long-term treatment with cisapride or antibiotics reversed altered small-intestinal motility and bacterial overgrowth in patients with liver cirrhosis. These findings suggest a possible role for prokinetics and antibiotics as a modality of treatment in selected cases of decompensated cirrhosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cisapride decreases intestinal transit time and inhibits intestinal bacterial overgrowth and bacterial translocation in animal models and cirrhosis patients.
“The prokinetic drug cisapride not only decreases intestinal transit time but also inhibits intestinal bacterial overgrowth and bacterial translocation, both in animal models150,151 and in patients with cirrhosis150,152.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [152]
Cites
Vantrappen, G., Janssens, J., Hellemans, J., & Ghoos, Y. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108740 · Cited by 815 · see citing works
Small bowel bacterial overgrowth in patients with alcoholic cirrhosis
Morencos, F. C., Castano, G. D. L. H., Ramos, L. M., Arias, M. J. L., Ledesma, F., & Romero, F. P. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02282340 · Cited by 246 · see citing works
Jejunal Manometry Patterns in Health, Partial Intestinal Obstruction, and Pseudoobstruction
Summers, R. W., Anuras, S., & Green, J. (1983) · Gastroenterology · doi:10.1016/s0016-5085(83)80009-2 · Cited by 233 · see citing works
Intestinal Endotoxins As Mediators of Hepatic Injury—An Idea Whose Time Has Come Again
Nolan, J. P. (1989) · Hepatology · doi:10.1002/hep.1840100523 · Cited by 203 · see citing works
Husebye, E., Skar, V., Høverstad, T., Iversen, T., & Melby, K. K. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90565-0 · Cited by 178 · see citing works
Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis
Pardo, A., Bartolí, R., Lorenzo-Zúñiga, V., Planas, R., Viñado, B., Riba, J., Cabré, E., Santos, J., Luque, T., Ausina, V., et al. (2000) · Hepatology · doi:10.1053/he.2000.5746 · Cited by 177 · see citing works
Martini, G. A., Phear, E. A., Ruebner, B. H., & Sherlock, S. (1957) · PubMed · Cited by 172 · see citing works
Small bowel bacterial overgrowth in patients with alcoholic cirrhosis
Morencos, F. C., Castano, G. D. L. H., Ramos, L. M., Arias, M. J. L., Ledesma, F., & Romero, F. P. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02065533 · Cited by 132 · see citing works
Abnormalities in proximal small bowel motility in patients with cirrhosis
Jaime Chesta, R., Defilippi, C., & Defilíppí, C. (1993) · Hepatology · doi:10.1002/hep.1840170513 · Cited by 127 · see citing works
Self-citationAltered Small Bowel Motility in Patients with Liver Cirrhosis Depends on Severity of Liver Disease
Madrid, A. M., Cumsille, F., & Defilíppí, C. (1997) · Digestive Diseases and Sciences · doi:10.1023/a:1018899611006 · Cited by 110 · see citing works
Self-citationGastrointestinal dysfunction in liver disease and portal hypertension
Quiqley, E. M. M. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02282341 · Cited by 70 · see citing works
Justus, P. G., Martin, J. L., Goldberg, D. A., et al. (1982) · Gastroenterology · doi:10.1016/s0016-5085(82)80014-0 · Cited by 68 · see citing works
Gastrointestinal transit in cirrhotic patients: Effect of hepatic encephalopathy and its treatment
Thiel, D. H. V., FAGIUOLI, S., Wright, H. I., Chien, M.-C., & Gavaler, J. S. (1994) · Hepatology · doi:10.1002/hep.1840190112 · Cited by 57 · see citing works
[Bacterial overgrowth in small intestine in patients with liver cirrhosis].
Jaime Chesta, R., Silva, M., Thompson, L., del Canto, E., & Defilíppí, C. (1991) · PubMed · Cited by 40 · see citing works
Orthotopic liver transplantation improves small bowel motility disorders in cirrhotic patients.
Madrid, A. M., Brahm, J., BUCKEL, E., Silva, G., & Defilíppí, C. (1997) · PubMed · Cited by 33 · see citing works
Self-citationSninsky, C. A., Ramphal, R., Gaskins, D., et al. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90334-8 · Cited by 23 · see citing works
[Patients with liver cirrhosis: mouth-cecum transit time and gastric emptying of solid foods].
Chesta, J., Lillo, R., Defilíppí, C., et al. (1991) · PubMed · Cited by 22 · see citing works
[Morphology of the myenteric plexus of the small intestine in patients with liver cirrhosis].
Chesta, J., & Smok, G. (1993) · PubMed · Cited by 8 · see citing works
La cisaprida no altera el intervalo Q-T prolongado en pacientes con cirrosis hepática
Quera, R., Ana María Madrid, S., Héctor Ugalde, P., et al. (2000) · Revista médica de Chile · doi:10.4067/s0034-98872000000800003 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Stadlbauer, V., Gustot, T., Bernardi, M., Canton, R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.024 · Cited by 906 · see citing works
Bacterial translocation (BT) in cirrhosis†
Wiest, R., & Garcia‐Tsao, G. (2005) · Hepatology · doi:10.1002/hep.20632 · Cited by 677 · see citing works
The gut microbiome and liver cancer: mechanisms and clinical translation
Yu, L.-X., & Schwabe, R. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.72 · Cited by 634 · see citing works
The role of the microbiome in NAFLD and NASH
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809302 · Cited by 523 · see citing works
The role of the gut microbiota in nonalcoholic fatty liver disease
Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457 · see citing works
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354 · see citing works
Interactions Between Commensal Bacteria and Gut Sensorimotor Function in Health and Disease
Barbara, G., Stanghellini, V., Brandi, G., Cremon, C., Nardo, G. D., De Giorgio, R., & Corinaldesi, R. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00230.x · Cited by 325 · see citing works
A Systematic Review of Diagnostic Tests for Small Intestinal Bacterial Overgrowth
Khoshini, R., Dai, S.-C., Lezcano, S., & Pimentel, M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0065-1 · Cited by 323 · see citing works
Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice
Hartmann, P., Chen, P., Wang, H. J., Wang, L., McCole, D. F., Brandl, K., Stärkel, P., Belzer, C., Hellerbrand, C., Tsukamoto, H., et al. (2013) · Hepatology · doi:10.1002/hep.26321 · Cited by 246 · see citing works
Non-alcoholic fatty liver and the gut microbiota
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.003 · Cited by 241 · see citing works
Gupta, A., Dhiman, R. K., Kumari, S., Rana, S., Agarwal, R., Duseja, A., & Chawla, Y. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.017 · Cited by 202 · see citing works
Gut-liver axis: Recent concepts in pathophysiology in alcohol-associated liver disease
Raya Tonetti, F., Eguileor, A., Mrdjen, M., Pathak, V., Travers, J., Nagy, L. E., & Llorente, C. (2024) · Hepatology · doi:10.1097/hep.0000000000000924 · Cited by 78 · see citing works
Quigley, E. M. M. (2007) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2007.07.012 · Cited by 67 · see citing works
Effect of cisapride on intestinal bacterial and endotoxin translocation in cirrhosis
Zhang, S.-C. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i3.534 · Cited by 42 · see citing works
Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers
Madsen, B. S., Havelund, T., & Krag, A. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0044-1 · Cited by 38 · see citing works
- Authors
- Madrid, A. M., Hurtado, C., Venegas, M., Cumsille, F., & Defilippi, C.
- Affiliations
- University of Chile (CL)
- Venue
- American Journal of Gastroenterology
- Published
- 2001-04
- Volume
- 96
- Issue
- 4
- Pages
- 1251-1255
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2053404936
- Cited by
- 158
- References
- 19
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 10 · 2023: 6 · 2022: 6 · 2021: 12 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 8 · 2015: 6 · 2014: 5 · 2013: 6 · 2012: 5
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- liver cirrhosis, cisapride, norfloxacin, neomycin, small intestine motility, small intestinal bacterial overgrowth, orocecal transit time, prokinetic agents, antibiotics, liver function, Child-Pugh score, decompensated cirrhosis
- MeSH terms
- Adult, Aged, Anti-Infective Agents, Anti-Bacterial Agents, Bacteria, Female, Gastrointestinal Agents, Gastrointestinal Motility, Humans, Liver Cirrhosis, Male, Middle Aged, Neomycin, Norfloxacin, Severity of Illness Index, Time Factors, Cisapride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
